TSHA-110 / Taysha Gene Therapies - LARVOL DELTA

Taysha Gene Therapies Announces New Data on Multiple Preclinical Programs and Upcoming R&D Day (Businesswire) - “Taysha Gene Therapies, Inc….today announced new data for multiple preclinical programs and a planned R&D Day, which will be held in June 2021.…We have advanced five programs into IND/CTA-enabling studies, including TSHA-105 in SLC13A5 deficiency…In SLC13A5 knockout mice, treatment with...TSHA-105 normalized electroencephalogram (EEG) brain activity, reduced the number of seizures, and reduced seizure susceptibility compared to vehicle-treated controls…In preclinical studies, TSHA-110 caused a significant, dose-dependent reduction of GM2 accumulation at 20 weeks in mice that were dosed intrathecally at postnatal day 1 or at 6 weeks of age. Long-term follow up studies, which include bi-monthly behavioral, as well as biochemical and histological analyses, are currently ongoing.”

Preclinical • CNS Disorders • Epilepsy